West Pharmaceutical Services (WST) Long-Term Deferred Tax (2009 - 2026)

West Pharmaceutical Services' Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $63.9 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 145.77% year-over-year to $63.9 million; the TTM figure through Mar 2026 stood at $63.9 million (up 145.77% YoY), while the FY2025 annual figure was $38.4 million, up 47.69% from the prior year.
• Long-Term Deferred Tax came in at $63.9 million for Q1 2026 at West Pharmaceutical Services, up from $38.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $99.0 million in Q1 2023 to a low of $17.3 million in Q3 2023.
• A 5-year average of $44.6 million and a median of $37.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax tumbled 78.79% in 2024 and surged 145.77% in 2026, its largest moves.
• West Pharmaceutical Services' Long-Term Deferred Tax stood at $65.6 million in 2022, then plunged by 60.82% to $25.7 million in 2023, then climbed by 1.17% to $26.0 million in 2024, then surged by 47.69% to $38.4 million in 2025, then surged by 66.41% to $63.9 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $63.9 million, $38.4 million, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison